PE20121585A1 - ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS - Google Patents
ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOSInfo
- Publication number
- PE20121585A1 PE20121585A1 PE2012000234A PE2012000234A PE20121585A1 PE 20121585 A1 PE20121585 A1 PE 20121585A1 PE 2012000234 A PE2012000234 A PE 2012000234A PE 2012000234 A PE2012000234 A PE 2012000234A PE 20121585 A1 PE20121585 A1 PE 20121585A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- ectodominium
- Prior art date
Links
- 102000056372 ErbB-3 Receptor Human genes 0.000 title 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 201000010174 renal carcinoma Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN ANTICUERPO CONTRA ErbB3 QUE COMPRENDE: A) UNA REGION VARIABLE DE CADENA PESADA QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 1 Y COMPRENDE UNA CDRH1 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 7, UNA CDRH2 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 8, Y UNA CDRH3 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 9; Y B) UNA REGION VARIABLE DE CADENA LIGERA QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 2 Y COMPRENDE UNA CDRL1 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 10, UNA CDRL2 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 11, Y UNA CDRL3 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 12. TAMBIEN SE REFIERE A UN METODO DE TRATAMIENTO DE CARCINOMA RENAL, CANCER DE PROSTATA, CANCER DE OVARIO Y CANCER PULMONAR QUE COMPRENDE ADMINISTRAR EL ANTICUERPO CONTRA ErbB3 Y OTRO COMPUESTO TAL COMO ERLOTINIB, TAXOL O CISPLATINO PARA OBTENER UN EFECTO SINERGICO EN LA SUPRESION DEL CRECIMIENTO DEL TUMOR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23579909P | 2009-08-21 | 2009-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121585A1 true PE20121585A1 (es) | 2012-11-29 |
Family
ID=43607614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000234A PE20121585A1 (es) | 2009-08-21 | 2010-08-23 | ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2467164A2 (es) |
| JP (1) | JP5752687B2 (es) |
| KR (1) | KR20120059568A (es) |
| CN (1) | CN103002912A (es) |
| AU (1) | AU2010284018C1 (es) |
| BR (1) | BR112012003809A2 (es) |
| CA (1) | CA2771744A1 (es) |
| CR (1) | CR20120108A (es) |
| DO (1) | DOP2012000044A (es) |
| EA (1) | EA201200195A1 (es) |
| EC (1) | ECSP12011740A (es) |
| IL (1) | IL218097A0 (es) |
| IN (1) | IN2012DN01518A (es) |
| MA (1) | MA33582B1 (es) |
| MX (1) | MX336091B (es) |
| NI (1) | NI201200027A (es) |
| PE (1) | PE20121585A1 (es) |
| SG (1) | SG178509A1 (es) |
| TN (1) | TN2012000057A1 (es) |
| WO (1) | WO2011022727A2 (es) |
| ZA (1) | ZA201201195B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2631727T3 (es) | 2007-02-16 | 2017-09-04 | Merrimack Pharmaceuticals, Inc. | Anticuerpos contra el ErbB3 y usos de los mismos |
| CN105999263B (zh) * | 2009-11-13 | 2021-06-29 | 第一三共欧洲有限公司 | 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法 |
| CN102822201B (zh) | 2009-12-22 | 2014-09-24 | 罗切格利卡特公司 | 抗her3抗体及其用途 |
| EP2544680B1 (en) | 2010-03-11 | 2015-01-14 | Merrimack Pharmaceuticals, Inc. | Use of erbb3 inhibitors in the treatment of triple negative breast cancer |
| BR112012025730B1 (pt) | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
| BR112013004012B1 (pt) | 2010-08-20 | 2021-03-23 | Novartis Ag | Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
| MX348637B (es) | 2010-11-01 | 2017-06-22 | Symphogen As | Anticuerpos y composiciones anti-her3. |
| KR101517320B1 (ko) | 2011-04-19 | 2015-05-28 | 메리맥 파마슈티컬즈, 인크. | 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체 |
| AU2012274461A1 (en) | 2011-06-20 | 2014-01-16 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbB3 antibody |
| MX357391B (es) | 2011-09-30 | 2018-07-06 | Regeneron Pharma | Anticuerpos anti-erbb3 y usos de los mismos. |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| CN103959065B (zh) | 2011-10-06 | 2018-07-17 | Aveo制药公司 | 预测肿瘤对抗erbb3抗体的应答 |
| EP2788377B1 (en) * | 2011-11-09 | 2019-01-23 | The UAB Research Foundation | Her3 antibodies and uses thereof |
| WO2013084147A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| WO2013124297A1 (en) * | 2012-02-22 | 2013-08-29 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| US20160232293A1 (en) * | 2013-10-17 | 2016-08-11 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| CA2941030C (en) | 2014-02-28 | 2025-05-13 | Merus N.V. | ANTIBODIES THAT BIND TO EGFR AND ERBB3 |
| CN110642952B (zh) * | 2014-08-14 | 2021-05-25 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| WO2016038610A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| EP3365373B1 (en) | 2015-10-23 | 2021-03-10 | Merus N.V. | Binding molecules that inhibit cancer growth |
| KR102905513B1 (ko) | 2017-03-31 | 2026-01-02 | 메뤼스 엔.페. | NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB-2 및 ErbB-3 결합 이중특이적 항체 |
| JP7296891B2 (ja) | 2017-05-17 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ |
| FI3665198T3 (fi) | 2017-08-09 | 2025-04-25 | Merus Nv | EGFR:ää ja cMET:tä sitovia vasta-aineita |
| EP3665200B1 (en) | 2017-08-09 | 2025-04-16 | University of Saskatchewan | Her3 binding agents and uses thereof |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| JP2021534811A (ja) * | 2018-06-22 | 2021-12-16 | シーアールディー ファーマシューティカルズ インコーポレイティド | 抗ｈｅｒ３抗体およびその用途 |
| KR20230086702A (ko) * | 2020-10-14 | 2023-06-15 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항-her3 항체 및 항-her3 항체-약물 접합체 및 이의 의학적 용도 |
| EP4247430A4 (en) * | 2020-11-20 | 2024-12-11 | Actinium Pharmaceuticals, Inc. | Her3 radioimmunotherapy for the treatment of solid cancers |
| AU2022293634A1 (en) * | 2021-06-15 | 2024-01-18 | Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. | Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof |
| CN119013307A (zh) * | 2022-04-13 | 2024-11-22 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段及其医药用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2631727T3 (es) * | 2007-02-16 | 2017-09-04 | Merrimack Pharmaceuticals, Inc. | Anticuerpos contra el ErbB3 y usos de los mismos |
-
2010
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/en not_active Ceased
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 MX MX2012002172A patent/MX336091B/es unknown
- 2010-08-23 EA EA201200195A patent/EA201200195A1/ru unknown
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 CA CA2771744A patent/CA2771744A1/en not_active Abandoned
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/ko not_active Withdrawn
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/zh active Pending
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/es not_active Application Discontinuation
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/pt not_active IP Right Cessation
- 2010-08-23 EP EP10810721A patent/EP2467164A2/en not_active Withdrawn
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/ja not_active Ceased
-
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/es unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/es unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/es unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/fr unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL218097A0 (en) | 2012-04-30 |
| ZA201201195B (en) | 2015-07-29 |
| MX336091B (es) | 2016-01-08 |
| CA2771744A1 (en) | 2011-02-24 |
| ECSP12011740A (es) | 2013-02-28 |
| EP2467164A2 (en) | 2012-06-27 |
| KR20120059568A (ko) | 2012-06-08 |
| EA201200195A1 (ru) | 2012-12-28 |
| JP5752687B2 (ja) | 2015-07-22 |
| BR112012003809A2 (pt) | 2019-09-24 |
| WO2011022727A3 (en) | 2013-06-27 |
| AU2010284018A1 (en) | 2012-03-22 |
| MA33582B1 (fr) | 2012-09-01 |
| AU2010284018C1 (en) | 2015-10-15 |
| CR20120108A (es) | 2012-06-05 |
| CN103002912A (zh) | 2013-03-27 |
| WO2011022727A2 (en) | 2011-02-24 |
| MX2012002172A (es) | 2012-05-29 |
| AU2010284018B2 (en) | 2014-06-05 |
| SG178509A1 (en) | 2012-04-27 |
| NI201200027A (es) | 2013-01-29 |
| DOP2012000044A (es) | 2012-06-30 |
| TN2012000057A1 (en) | 2013-09-19 |
| JP2013506622A (ja) | 2013-02-28 |
| IN2012DN01518A (es) | 2015-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121585A1 (es) | ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| EA201490369A1 (ru) | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek | |
| AR077595A1 (es) | Tratamientos de combinacion | |
| EP4538372A3 (en) | Anti-trop2 antibody | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| UA106890C2 (uk) | Гуманізоване антитіло до cdcp1 | |
| MX2020012799A (es) | Composicion y metodo para tratar el cancer asociado con mutacion del egfr. | |
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| NZ783685A (en) | Antibodies and conjugates thereof | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| AR091220A1 (es) | Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| SG10201906075VA (en) | Methods of treating cancer | |
| BR112014024017A8 (pt) | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| NZ592369A (en) | Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment | |
| EP3722810A3 (en) | Molecular profiling of tumors | |
| AR094849A1 (es) | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento de cáncer | |
| NZ606195A (en) | Methods and compositions for liver cancer therapy | |
| AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
| CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
| GB201114051D0 (en) | Compounds and their uses | |
| WO2011146568A8 (en) | Predicting response to a her inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |